Breast Cancer Liquid Biopsy Market To Hit USD 1.9 Billion By 2032, Says Global Market Insights Inc.

(MENAFN- GlobeNewsWire - Nasdaq) Breast cancer liquid biopsy industry is projected to witness a CAGR of 22.6% during the period 2024-2032. This growth can be attributed to the rising awareness for early diagnosis and treatment.

Selbyville, Delaware, Jan. 06, 2025 (GLOBE NEWSWIRE) --

Breast cancer liquid biopsy market size reached USD 305.9 million in 2023 and is projected to expand at a robust CAGR of 22.6% from 2024 to 2032. Rising breast cancer incidence and advancements in diagnostic technologies are driving this growth. Liquid biopsy innovations, including next-generation sequencing (NGS), are gaining traction due to their high accuracy and minimally invasive methods, making early detection and personalized treatment more accessible and effective.

Request for a sample of this research report @

Increased awareness around genetic predispositions and inherited cancer risks is further fueling the demand for these technologies. Liquid biopsy techniques support more precise, individualized treatment plans by providing detailed molecular insights that help guide targeted cancer therapies.

Segmented by biomarker type, the breast cancer liquid biopsy market from cfDNA segment is expected to maintain a strong CAGR of 22.5% in 2023. This popularity is attributed to cfDNA's ability to reveal real-time tumor dynamics, offering early detection and insights into treatment response and disease progression. Compared to traditional tissue biopsies, cfDNA provides a comprehensive genomic profile and can detect emerging mutations linked to drug resistance, increasing its utility in cancer diagnostics.

In terms of products and services, the market is divided into kits & reagents and service offerings, with kits & reagents holding a significant 67.1% share in 2023. These components play a pivotal role in the liquid biopsy, thus facilitating non-invasive diagnostic procedures. The rising prevalence of breast cancer has intensified demand for these kits, driving ongoing research and new product launches in early cancer detection.

North America breast cancer liquid biopsy market in 2023, with a valuation of USD 133.3 million. The country's advanced healthcare infrastructure and substantial R&D investments foster the implementation of liquid biopsy technologies as non-invasive substitutes to traditional methods. The escalating incidence of breast cancer in the U.S. has further spurred demand for these innovative diagnostic tools, underscoring the region's leadership in this market.

As a result, the global breast cancer liquid biopsy market is expected to grow significantly, driven by technology innovations, early cancer detection efforts, and a growing emphasis on patient-specific treatment strategies. This expansion reflects the increasing shift toward minimally invasive diagnostic techniques that offer improved accuracy and patient outcomes.

Request for Report Customization @

Major players in breast cancer liquid biopsy market include Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, QIAGEN, Sysmex, System Biosciences, Thermo Fisher Scientific, and Twist Bioscience among others.

Partial Table of Contents (ToC) of the report:

Chapter 1 Methodology & Scope

1.1 Market scope & definition

1.2 Research design

1.2.1 Research approach

1.2.2 Data collection methods

1.3 Base estimates & calculations

1.3.1 Base year calculation

1.3.2 Key trends for market estimation

1.4 Forecast model

1.5 Primary research and validation

1.5.1 Primary sources

1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Rising prevalence of breast cancer

3.2.1.2 Technological advancements in liquid biopsy technique

3.2.1.3 Rising awareness for early diagnosis and treatment

3.2.1.4 Expansion of research and development

3.2.2 Industry pitfalls & challenges

3.2.2.1 High cost of biopsy devices

3.2.2.2 Stringent regulatory requirements

3.3 Growth potential analysis

3.4 Epidemiology scenario

3.5 Regulatory landscape

3.6 Technological landscape

3.7 Porter's analysis

3.8 PESTEL analysis

Browse more diagnostic devices industry reports @

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

MENAFN06012025004107003653ID1109057828